MC2 THERAPEUTICS
MC2 Therapeutics drives innovation and program development from a lean core organization in close collaboration with a network of highly specialized, fully integrated and contributing experts and service providers. In addition to our core team, MC2 Therapeutics employs a large number of retained external contributors and consultants enabling us to bring further expertise to our work.
MC2 THERAPEUTICS
Social Links:
Industry:
Pharmaceutical Therapeutics
Founded:
2006-01-01
Address:
Hørsholm, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.mc2therapeutics.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager WordPress Apache Global Site Tag Sitelinks Search Box Euro
Similar Organizations
Corino Therapeutics
Corino Therapeutics is a private, development-stage biopharmaceutical company
Emplicure
Emplicure is a privately held Swedish research and product development focused pharmaceutical company.
Laboratorios Atral
Laboratorios Atral is a privately owned group of pharmaceutical company
Therawis
Therawis Pharma GmbH is a privately held, profitable oncology-specialized company.
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-09 | Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer |
Official Site Inspections
http://www.mc2therapeutics.com Semrush global rank: 5.78 M Semrush visits lastest month: 1.44 K
- Host name: dedi5059.your-server.de
- IP address: 136.243.123.133
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "MC2 Therapeutics"
Welcome to MC2 Therapeutics
Nov 14, 2024 · Our two first-in-class and novel mode of action drug candidates are “I&I pipeline in a drug” as they both have potential in multiple major underserved indications. We carefully …See details»
Management - MC2 Therapeutics
MC2 Therapeutics drives innovation and program development from a lean core organization in close collaboration with a network of highly specialized, fully integrated and contributing experts and service providers.See details»
About us - MC2 Therapeutics
MC2 Therapeutics is a commercial biotech company developing novel treatment paradigms for immunology and inflammation (“I&I”) diseases for which there are no or very limited approved …See details»
MC2 Therapeutics - LinkedIn
MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions.See details»
MC2 Therapeutics - Crunchbase Company Profile
MC2 Therapeutics drives innovation and program development from a lean core organization in close collaboration with a network of highly specialized, fully integrated and contributing experts and service providers.See details»
MC2 Therapeutics - LinkedIn
MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions.See details»
MC2 Therapeutics Announces Positive Phase 2a Results of
Copenhagen, October 11th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory …See details»
MC2 Therapeutics Announces Completion of Enrollment in MC2 …
Copenhagen, December 7th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory …See details»
MC2 Therapeutics - Psoriasis
MC2 Therapeutics is a proud partner of the National Psoriasis Foundation (NPF). Please visit their website below for more information on psoriasis: https://www.psoriasis.org/See details»
MC2 Therapeutics Announces U.S. Food and Drug
Jul 22, 2020 · With the US approval, the recent submission of its marketing authorization application of Wynzora ® Cream in EU, and its ongoing interactions with payers, physicians and patient organizations...See details»
MC2 Therapeutics Announces Collaboration Agreement with EPI …
Aug 24, 2020 · MC2 Therapeutics retains full ownership of WYNZORA Cream under the Collaboration Agreement and MC2 Therapeutics and EPI Health will utilize their combined …See details»
MC2 Therapeutics A/S - BIO CEO & Investor Conference | BIO
Feb 7, 2023 · MC2 Therapeutics is a privately held commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for …See details»
MC2 Therapeutics Announces Completion of Enrollment in
Copenhagen, December 7th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory …See details»
MC2 Therapeutics Receives Positive Feedback from FDA
May 13, 2024 · MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms for neutrophilic diseases. Its pioneering approach in immunology is …See details»
Investors - MC2 Therapeutics
The majority owner is Mads Clausen, grandson of Danish industrialist and Founder of Danfoss A/S. MC2 Therapeutics is a privately held company that is supported by strong owners. Read …See details»
MC2 Therapeutics announces breakthrough discovery with the …
Sep 1, 2022 · MC2 Therapeutics A/S is a privately held commercial stage pharmaceutical company committed to research and development of novel treatment paradigms for people …See details»
MC2 Therapeutics announces initiation of a Phase 2 clinical trial in …
Sep 14, 2022 · MC2-25 Cream is an innovative new drug candidate, addressing MC2's new biological treatment paradigm for treatment of urea associated skin diseases. MC2-25 Cream …See details»
Pipeline - MC2 Therapeutics
MC2 Therapeutics is advancing in multiple areas with PAD™️ Cream Technology. The pipeline includes multiple PAD™ Cream psoriasis medications. Learn More.See details»
MC2 Therapeutics Announces Positive Phase 2a Results of Novel …
Copenhagen, October 11th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory …See details»
News - MC2 Therapeutics
Copenhagen, November 14, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, …See details»